Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Shanghai - Delayed Quote • CNY Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS) Follow Compare 18.79 +0.72 +(3.98%) At close: February 21 at 3:00:03 PM GMT+8 Comparisons Indicators Technicals Corporate Events Line Candle Baseline Mountain Bar Step Baseline Delta HLC Wave Scatterplot Histogram Range Channel Colored Line Colored Mountain Colored Step Colored Bar Colored HLC Volume Candle Hollow Candle Step Mountain Verex Line Vertex Step Vertex Mountain Vertex Baseline Delta Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 688321.SS 1D 5D 2.12% 1M 9.24% 3M -18.90% 6M 11.05% YTD 1.13% 1Y 14.99% 5Y -70.06% All -84.97% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours 1 day 1 week 1 month 3 months Recent News: 688321.SS View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations The Phase III clinical trial application for first-line treatment of extensive disease small cell lung cancer with Chiauranib has been approved Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets: Investigational New Drug (IND) Application Accepted Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma Positive results from Phase II clinical trial (CGZ203 study) of Chiglitazar monotherapy for non-alcoholic steatohepatitis Related Tickers 2096.HK Simcere Pharmaceutical Group Limited 7.900 +2.33% 6185.HK CanSino Biologics Inc. 35.000 -1.41% 0013.HK HUTCHMED 25.450 +6.93% HCM HUTCHMED (China) Limited 16.11 +5.09%